Thank you, I can help clarify as it appears Bioshares (just...

Thank you, I can help clarify as it appears Bioshares (just curious does anyone know how many subscribers to they have?) haven’t delineated their LBT product research clearly:

APAS Compact: FDA clearance due anytime now
APAS Independence: FDA supplementary Clearance due later this year (yet to be submitted) as this covers highly advance automated robotic plate handling technology, sophistically integrated with Hettich’s leading incubation technology to be a potential FMLA killer.

So let’s focus on near term sales of APAS Compact:

APAS Compact will be ready to sell this year given FDA asap, and Demo Day at ECCMID on 9th April. The distributor agreement is critical, and when signed, I would expect a USD $25million to $50m USD minimum payment rights to sell the complete LBT APAS range.

APAS Compact will have a 2 year, first to market lead, according to a HC post citing Bioshares (?) and will penetrate the global microbiology market hard given no comparable FDA cleared product offering.

A cutting edge independent solution to 27,000 small to medium target market (refer to source table below) for APAS Compact Plate Reader, at an estimated price of US$100,000, means a total ‘potential’ global sales of US $2.7 billion in potential sales.

LBT can hopefully capture 20% market = LBT revenues of US $540 million over the next 2 years.

Hopefully Bioshares is right with the 2 year lead!

Source LBT asx ann: